Results 51 to 60 of about 19,163 (188)

The Cytotoxicity and Clearance of Mutant Huntingtin and Other Misfolded Proteins

Cells, 2021
Protein misfolding and aggregation are implicated in many neurodegenerative diseases. One of these diseases is Huntington’s, which is caused by increased glutamine-encoding trinucleotide repeats within the Huntingtin gene.
Austin Folger, Yanchang Wang
doaj   +1 more source

Huntingtin associated protein 1 and its functions [PDF]

Cell Adhesion & Migration, 2009
Huntington disease (HD) is caused by a polyglutamine expansion in the protein huntingtin (Htt). Several studies suggest that Htt and huntingtin associated protein 1 (HAP1) participate in intracellular trafficking and that polyglutamine expansion affects vesicular transport.
Zhou, Xin-Fu, Wu, Linyan
openaire   +3 more sources

Rapamycin reduces neuronal mutant huntingtin aggregation and ameliorates locomotor performance in Drosophila

Frontiers in Aging Neuroscience, 2023
Huntington’s disease (HD) is a neurodegenerative disease characterized by movement and cognitive dysfunction. HD is caused by a CAG expansion in exon 1 of the HTT gene that leads to a polyglutamine (PQ) repeat in the huntingtin protein, which aggregates ...
Jonathan R. Roth, Jonathan R. Roth, Ruan Carlos Macedo de Moraes, Brittney P. Xu, Savannah R. Crawley, Malghalara A. Khan, Girish C. Melkani   +6 more
doaj   +1 more source

A proteomic investigation of forebrain regeneration in the leopard gecko (Eublepharis macularius)

Developmental Dynamics, EarlyView.
Our investigation reveals ontogenetic, injury‐ and regeneration‐associated proteomic changes in the leopard gecko forebrain. Abstract Background The ability to replace lost or damaged neurons following an injury is termed reactive neurogenesis. Although reactive neurogenesis has been reported in several lizard species, the molecular mechanisms ...
Alexandra I. Noble, Samantha L. Payne, Matthew K. Vickaryous   +2 more
wiley   +1 more source

Mechanisms of copper ion mediated Huntington's disease progression. [PDF]

PLoS ONE, 2007
Huntington's disease (HD) is caused by a dominant polyglutamine expansion within the N-terminus of huntingtin protein and results in oxidative stress, energetic insufficiency and striatal degeneration.
Jonathan H Fox, Jibrin A Kama, Gregory Lieberman, Raman Chopra, Kate Dorsey, Vanita Chopra, Irene Volitakis, Robert A Cherny, Ashley I Bush, Steven Hersch   +9 more
doaj   +1 more source

Crosstalk Between Parkinson's Disease and Colorectal Cancer: Genetic Mechanisms, Gut Microbiota, and Therapeutic Insights

Health Care Science, EarlyView.
This review elucidates the crosstalk between Parkinson's disease and colorectal cancer, driven by shared genetics (PRKN, PINK1, DJ‐1) involving oxidative stress, cell cycle regulation, and inflammation. It identifies the gut microbiota—via functional amyloids and short‐chain fatty acids (SCFAs)—as a mechanistic bridge, offering insights for dual ...
Jiacheng Ying, Zhengyuan Fang, Cheng Zhang, Xu Liu, Jianzhi Cui, Zezhi Li, Jiayin Tang   +6 more
wiley   +1 more source

Isolation of a 40-kDa Huntingtin-associated Protein [PDF]

Journal of Biological Chemistry, 2001
Huntington's disease is caused by an expanded CAG trinucleotide repeat coding for a polyglutamine stretch within the huntingtin protein. Currently, the function of normal huntingtin and the mechanism by which expanded huntingtin causes selective neurotoxicity remain unknown. Clues may come from the identification of huntingtin-associated proteins (HAPs)
M F, Peters, C A, Ross
openaire   +2 more sources

Proteasome activator enhances survival of Huntington's disease neuronal model cells. [PDF]

PLoS ONE, 2007
In patients with Huntington's disease (HD), the proteolytic activity of the ubiquitin proteasome system (UPS) is reduced in the brain and other tissues. The pathological hallmark of HD is the intraneuronal nuclear protein aggregates of mutant huntingtin.
Hyemyung Seo, Kai-Christian Sonntag, Woori Kim, Elena Cattaneo, Ole Isacson   +4 more
doaj   +1 more source

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025

Movement Disorders, EarlyView.
Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova, Jenny Townhill, Juliana Bronzova, Viktoria Andreeva, Swati Sathe, Cristina Sampaio   +5 more
wiley   +1 more source

Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice. [PDF]

PLoS ONE, 2013
Huntington's disease (HD) is an autosomal dominant, progressive and fatal neurological disorder caused by an expansion of CAG repeats in exon-1 of the huntingtin gene.
Douglas Young, Franziska Mayer, Nella Vidotto, Tatjana Schweizer, Ramon Berth, Dorothee Abramowski, Derya R Shimshek, P Herman van der Putten, Peter Schmid   +8 more
doaj   +1 more source